These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 7925528)

  • 1. Intracavernous calcitonin gene-related peptide plus prostaglandin E1: possible alternative to penile implants in selected patients.
    Truss MC; Becker AJ; Thon WF; Kuczyk M; Djamilian MH; Stief CG; Jonas U
    Eur Urol; 1994; 26(1):40-5. PubMed ID: 7925528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcitonin-gene-related peptide: a possible role in human penile erection and its therapeutic application in impotent patients.
    Stief CG; Wetterauer U; Schaebsdau FH; Jonas U
    J Urol; 1991 Oct; 146(4):1010-4. PubMed ID: 1895414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostaglandin E1 versus phentolamine/papaverine for the treatment of erectile impotence: a double-blind comparison.
    Lee LM; Stevenson RW; Szasz G
    J Urol; 1989 Mar; 141(3):549-50. PubMed ID: 2918589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Followup results of a combination of calcitonin gene-related peptide and prostaglandin E1 in the treatment of erectile dysfunction.
    Djamilian M; Stief CG; Kuczyk M; Jonas U
    J Urol; 1993 May; 149(5 Pt 2):1296-8. PubMed ID: 8479019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prostaglandin E1 in erectile dysfunction].
    Porst H
    Urologe A; 1989 Mar; 28(2):94-8. PubMed ID: 2655258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Objective double-blind evaluation of erectile function with intracorporeal papaverine in combination with phentolamine and/or prostaglandin E1.
    Allen RP; Engel RM; Smolev JK; Brendler CB
    J Urol; 1992 Oct; 148(4):1181-3. PubMed ID: 1404632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Papaverine-phentolamine and prostaglandin E1 versus papaverine-phentolamine alone for intracorporeal injection therapy: a clinical double-blind study.
    Shenfeld O; Hanani J; Shalhav A; Vardi Y; Goldwasser B
    J Urol; 1995 Sep; 154(3):1017-9. PubMed ID: 7637045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostaglandin E1 with phentolamine for the treatment of erectile dysfunction.
    Meinhardt W; de la Fuente RB; Lycklama à Nijeholt AA; Vermeij P; Zwartendijk J
    Int J Impot Res; 1996 Mar; 8(1):5-7. PubMed ID: 8735187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracavernous injection of prostaglandin E1 in combination with papaverine: enhanced effectiveness in comparison with papaverine plus phentolamine and prostaglandin E1 alone.
    Floth A; Schramek P
    J Urol; 1991 Jan; 145(1):56-9. PubMed ID: 1984099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of a mixture of papaverine, phentolamine and prostaglandin E1 with other intracavernous injections.
    Meinhardt W; Lycklama à Nijeholt AA; Kropman RF; Vermeij P; Zwartendijk J
    Eur Urol; 1994; 26(4):319-21. PubMed ID: 7713130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficiency and side effects of prostaglandin E1 in the treatment of erectile dysfunction.
    Waldhauser M; Schramek P
    J Urol; 1988 Sep; 140(3):525-7. PubMed ID: 3045341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Intracavernous injection of vasoactive drugs for treating erectile impotence].
    Yasumoto R; Asakawa M; Kawashima H; Yoshimura R; Maekawa T; Kashiwara N; Tanaka H; Nishio S
    Hinyokika Kiyo; 1988 Feb; 34(2):301-4. PubMed ID: 2454019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of responses to adrenomedullin and calcitonin gene-related peptide in the feline erection model.
    Champion HC; Wang R; Santiago JA; Murphy WA; Coy DH; Kadowitz PJ; Hellstrom WJ
    J Androl; 1997; 18(5):513-21. PubMed ID: 9349749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prostaglandin E1 in the diagnosis and therapy of erectile disorders].
    Loran OB; Segal AS; Shcheplev PA
    Urol Nefrol (Mosk); 1995; (4):35-8. PubMed ID: 7571200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study of papaverine plus phentolamine versus prostaglandin E1 in erectile dysfunction.
    Bechara A; Casabé A; Chéliz G; Romano S; Rey H; Fredotovich N
    J Urol; 1997 Jun; 157(6):2132-4. PubMed ID: 9146599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prostaglandin E1 (PGE1) in diagnosis and long-term therapy of erectile dysfunction].
    Derouet H; Weirauch A; Bewermeier H
    Urologe A; 1996 Jan; 35(1):62-7. PubMed ID: 8851852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Intracavernous pharmacotherapy for treatment and evaluation of impotence].
    Vardi Y; Lidgi S; Moskovitz B; Levin RD
    Harefuah; 1991 Oct; 121(7-8):223-5. PubMed ID: 1783307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracavernous pharmacotherapy for impotence: selection of appropriate agent and dose.
    von Heyden B; Donatucci CF; Kaula N; Lue TF
    J Urol; 1993 May; 149(5 Pt 2):1288-90. PubMed ID: 8479018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Value of prostaglandin El in the diagnosis of erectile dysfunction in comparison with papaverine and papaverine/phentolamine in 61 patients with erectile dysfunction].
    Porst H
    Urologe A; 1988 Jan; 27(1):22-6. PubMed ID: 3284144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracavernous self-injection therapy for the treatment of erectile dysfunction.
    Chiang HS; Wen TC; Wu CC; Chiang WH
    J Formos Med Assoc; 1992 Sep; 91(9):898-901. PubMed ID: 1363391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.